

Listing of the Claims:

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

1-23. (Cancelled)

24. (Currently Amended) An isolated ~~stabilizing molecule~~ peptide which binds to and stabilizes the native conformation state of a first polypeptide, but not a denatured conformation state of the first polypeptide, in which the ~~stabilizing molecule~~ peptide comprises a fragment of a second polypeptide, said fragment comprising 600 amino acids or fewer of said second polypeptide, and binds to a site of the first polypeptide which at least partially overlaps a functional site of the first polypeptide, ~~and in which the stabilizing molecule does not consist of a natural binding partner of the polypeptide.~~

25. (Currently Amended) The ~~stabilizing molecule~~ peptide of Claim 24, in which the first polypeptide is human p53.

26. (Currently Amended) The ~~stabilizing molecule~~ peptide of Claim 25, in which the polypeptide is p53 which comprises a mutation, selected from R175H, G245S, R248Q, R249S, R273H, R282W and I195T in which the mutation results in reversible denaturation of the polypeptide.

27. (Currently Amended) The ~~stabilizing molecule~~ peptide of Claim 24, in which the stabilising molecule comprises a polypeptide having the sequence REDEDEIEW (SEQ ID NO: 1).

28. (Cancelled)

29. (Currently Amended) The ~~stabilizing molecule~~ peptide of claim ~~28~~ 24 wherein said ~~molecule~~ peptide is derivatised with a sugar, phosphate, amine, amide, sulphate, sulphide, biotin, a fluorophore or a chromophore.

30 - 38. (Cancelled)

39. (Currently Amended) The ~~stabilizing molecule~~ peptide of claim 24 in which the ~~stabilizing molecule~~ peptide is derivatised with a fluorophore.

40. (Currently Amended) The ~~stabilizing molecule~~ peptide of claim 39 wherein said fluorophore is fluorescein.

41 – 43. (Cancelled).

44. (Currently Amended) A pharmaceutical composition comprising a ~~stabilizing molecule~~ peptide according to claim 24, together with a pharmaceutically acceptable carrier, diluent or excipient.

45. (Currently Amended) A pharmaceutical composition comprising a ~~polypeptide~~ peptide consisting of ~~having~~ the sequence REDEDEIEW (SEQ ID NO: 1) together with a pharmaceutically acceptable carrier, diluent or excipient.

46 – 47. (Cancelled)

48. (New) A peptide that binds to and stabilizes the wild-type conformation of a human p53 polypeptide, but not a mutant conformation of human p53 polypeptide, said peptide comprising 200 amino acids or fewer.

49. (New) The peptide of claim 48 which comprises the sequence REDEDEIEW (SEQ ID NO: 1).

50. (New) The peptide of claim 49 which consists of the sequence REDEDEIEW (SEQ ID NO: 1).

51. (New) The peptide of claim 24, in which the peptide consists of the sequence REDEDEIEW (SEQ ID NO: 1).